Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CVS HEALTH Corp Director's Dealing 2017

Sep 15, 2017

29875_dirs_2017-09-15_e699ae88-27ce-4d39-87d3-b3a819a0c16f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CVS HEALTH Corp (CVS)
CIK: 0000064803
Period of Report: 2017-08-23

Reporting Person: MERLO LARRY J (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-08-23 Common Stock G 14163 $77.61 Disposed 299254.5612 Direct
2017-09-13 Common Stock M 241150 $34.96 Acquired 540404.5612 Direct
2017-09-13 Common Stock S 241150 $83.07 Disposed 299254.5612 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-09-13 Stock Option $34.96 M 241150 Disposed 2018-04-01 Common Stock (241150) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 365115.6172 Indirect
Common Stock (restricted) 184116 Direct
ESOP Common Stock 6643.1158 Indirect
Stock Unit 612504.7457 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Phantom Stock Credits $1.00 Common Stock (5139.61) 5139.61 Direct
Stock Option $45.07 2019-04-02 Common Stock (332736) 332736 Direct
Stock Option $54.53 2020-04-01 Common Stock (314713) 314713 Direct
Stock Option $74.29 2021-04-01 Common Stock (335697) 335697 Direct
Stock Option $102.26 2022-04-01 Common Stock (273929) 273929 Direct
Stock Option $104.82 2023-04-01 Common Stock (286787) 286787 Direct
Stock Option $78.05 2024-04-03 Common Stock (338105) 338105 Direct

Footnotes

F1: All sales were effected pursuant to a Rule 10b5-1 plan.

F2: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sale prices ranging between $82.22 and $83.68 per share.

F3: Option became exercisable in four equal annual installments, commencing 4/1/2012.

F4: Each share credit is equivalent to one share; 1-for-1 conversion.

F5: Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.

F6: Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.

F7: Option became exercisable in four equal annual installments, commencing 4/2/2013.

F8: Option became exercisable in four equal annual installments, commencing 4/1/2014.

F9: Option became exercisable in four equal annual installments, commencing 4/1/2015.

F10: Option became exercisable in four equal annual installments, commencing 4/1/2016.

F11: Option became exercisable in four equal annual installments, commencing 4/1/2017.

F12: Option becomes exercisable in four equal annual installments, commencing 4/3/2018.